The goal of our team is to provide an economic analysis for the use of iMDA which will include a cost-effectiveness and cost-benefit analysis. Our economic analysis will provide a measure of cost per case averted for each iMDA intervention strategy as compared to current malaria interventions. Both provider and societal perspectives on costs will be calculated, including explicit measures of the impact of iMDA on human and livestock health and productivity.
The BOHEMIA team at the University of Virginia is working with researchers at Virginia Tech in assessing the economic impact of BOHEMIA. Work covered by UVA team is a sub-study of the BOHEMIA program. Activities for this study will be conducted in conjunction with the BOHEMIA clinical trial. The BOHEMIA clinical trial is a cluster randomized, parallel arm, controlled and double blinded trial testing the efficacy of ivermectin mass drug administration (iMDA) on malaria-related epidemiological outcomes when given simultaneously to humans and livestock.